
AcouSort invited to give a lecture at the Acoustofluidics conference

AcouSort's Senior Scientist Mikael Evander has been asked to give an invited lecture at *Acoustofluidics 2023*, which celebrates its 20th anniversary this year. *Acoustofluidics* is a conference dedicated to exploring the science, the engineering, and the use of micro and nanoscale acoustofluidics. The first conference was held in 2003 as part of a UK based network called USWnet. Today, the conference has grown into an international event gathering researchers working with all different aspects of acoustofluidics and its applications within life sciences.

The opportunity to give an invited lecture at an event like acoustofluidics is a significant recognition of AcouSort's commercial as well as scientific contribution to the field. AcouSort is relentlessly working to establish acoustofluidics as the next Gold Standard for automated sample preparation at the same time as the Company strives to push the technological and scientific boundaries of the technology even further.

The conference will be held in St. Louis, Missouri, so participation will also provide an excellent opportunity to make demo visits in the US to follow up on the leads gathered at BIO2023 and CYTO during early summer.

"The request to Mikael for giving an invited lecture at Acoustofluidics 2023 makes us very proud, and the conference will provide a fantastic opportunity for presenting AcouSort and our technology to our scientific peers," says AcouSort's CEO Torsten Freltoft.

Acoustofluidics 2023: <https://acoustofluidics.net/>

For further information on AcouSort, please contact:

Torsten Freltoft, CEO

Telephone: +45 2045 0854

E-mail: torsten.freltoft@acousort.com

About AcouSort

AcouSort AB (corporate registration number 556824-1037) is an innovative technology company focusing on developing products and solutions for integrated preparation of biological samples. With the help of sound waves, the company's products can separate blood cells, concentrate, purify, and stain cells, exosomes, and bacteria from biological samples. The technology of the company's products is acoustofluidics, where sound waves and microfluidics enable automated handling of samples in a range of application areas, from research on new biomarkers to the development of new diagnostic systems for near-patient testing – so-called Point-of Care (POC) systems. The company's commercialization strategy is based on the already proven business model of providing separation modules to diagnostic system manufacturers for integrated sample preparation as well as to continue the commercialization of the company's research instruments. With the help of the company's products and development of point-of-care tests, new diagnostic systems and treatments are enabled, addressing some of the most challenging disease areas of our time: cancer, infectious diseases, and cardiovascular diseases. AcouSort is listed at Nasdaq First North Growth Market. The company's Certified Adviser is Erik Penser Bank.